对比增强乳腺X线摄影前瞻性评估新辅助治疗后病理缓解的早期预测
这项前瞻性单中心先导研究连续纳入36例接受新辅助治疗的乳腺癌患者,在基线及首周期新辅助治疗前后行对比增强乳腺X线摄影。病灶最长径缩小百分比(CLD)≥20.93%可独立预测病理完全缓解(OR 9.52,P=0.02),敏感度73%、特异度88%;RECIST 1.1标准缓解与病理完全缓解无显著关联(P=0.24)。
要点
- 首周期新辅助治疗后CEM病灶最长径缩小≥20.93%可独立预测pCR,敏感度73%、特异度88%。
- RECIST 1.1标准评估的缓解与pCR无显著关联(OR 3.22,P=0.24)。
- 激素受体阴性乳腺癌中CLD≥20.93%与pCR可能性升高相关(OR 40.00,AUC 0.86)。
核心结论
- 首周期新辅助治疗后CEM测得的最长径缩小百分比可能是乳腺癌pCR的早期预测指标。
研究设计与样本
- 前瞻性单中心先导研究,连续纳入36例接受新辅助治疗的乳腺癌患者,于基线(2018年5月至2018年12月)及首周期新辅助治疗前后行CEM,由两名乳腺影像医师独立评估CLD和RECIST 1.1标准,以病理完全缓解为参考标准。
诊断标准与关键数值
- CLD≥20.93%独立预测pCR(OR 9.52,95%CI 1.34–67.23,P=0.02),敏感度73%(8/11)、特异度88%(22/25)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To assess whether changes in contrast-enhanced mammography (CEM)-derived lesion measurements after the first cycle of neoadjuvant therapy (NAT) can predict pathologic complete response (pCR) in individuals with breast cancer. Materials and Methods This prospective single-center pilot study enrolled consecutive participants with breast cancer treated with NAT who underwent CEM at baseline (May 2018 to December 2018). CEM was performed before and after the first cycle of NAT. Two breast radiologists independently evaluated the percentage change in the longest dimension of the lesion (CLD) and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria at CEM. Multivariable logistic regression was used to identify independent predictors of pCR, and predictive performance was assessed using area under the receiver operating characteristic curve (AUC). Results Thirty-six participants (mean age ± SD, 48 years ± 10.3) were included; 11 (30.5%) participants achieved pCR. A CLD of at least 20.93% independently predicted pCR (odds ratio, 9.52; 95% CI: 1.34, 67.23; P = .02), achieving a sensitivity of 73% (eight of 11) and a specificity of 88% (22 of 25). Response according to RECIST 1.1 criteria was not associated with pCR (odds ratio, 3.22; 95% CI: 0.46, 22.53; P = .24). In participants with hormone-receptor negative breast cancer, a CLD of at least 20.93% was associated with a higher likelihood of pCR (odds ratio, 40.00; 95% CI: 2.01, 794.27; P = .005) and had an AUC of 0.86 (95% CI: 0.65, >0.99; P = .005). Conclusion CLD at CEM after the first cycle of NAT may be an early predictor of pCR in individuals with breast cancer. Keywords: Breast, Tumor Response, Mammography, Oncology, Neoadjuvant Therapy, Radiographic Image Enhancement, Pathologic Complete Response, Breast Tumor Supplemental material is available for this article. © RSNA, 2025.
引用
- Pires-Gonçalves L, Aguiar AT, Leal C, et al. Prospective Evaluation of Contrast-enhanced Mammography for Early Prediction of Pathologic Response after Neoadjuvant Therapy. Radiol Imaging Cancer. 2025. PMID: 40407620. doi:10.1148/rycan.240117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。